首页> 外文期刊>IDrugs: the investigational drugs journal >American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.
【24h】

American Association for Cancer Research--100th Annual Meeting. New therapeutic developments: part 2. 18-22 April 2009, Denver, CO, USA.

机译:美国癌症研究协会-第100届年会。新疗法的发展:第2部分。2009年4月18日至22日,美国科罗拉多州丹佛。

获取原文
获取原文并翻译 | 示例
           

摘要

The naturally occurring compound PM-01183 (PharmaMar SA) Is an alkaloid that binds DNA, causing delayed progression of the S phase of the cell cycle and cycle arrest at G_2M. Pablo M Aviles from PharmaMar described a study in which the cytotoxicity of PM-01183 was examined in CHO-derived isogenic cell lines with normal or impaired DNA repair function. In nucleotide excision repair (NER)-deficient cells, the compound was 3- to 4-fold less potent than in normal cells, but was 100-fold more potent in homologous recombinant (HR)-deficient cells.
机译:天然存在的化合物PM-01183(PharmaMar SA)是一种结合DNA的生物碱,可导致细胞周期S期进程延迟并在G_2M处停滞。来自PharmaMar的Pablo M Aviles描述了一项研究,其中在具有正常或受损DNA修复功能的CHO衍生的同基因细胞系中检查了PM-01183的细胞毒性。在缺乏核苷酸切除修复(NER)的细胞中,该化合物的效力比正常细胞低3至4倍,但在同源重组(HR)缺乏的细胞中该化合物的效力高100倍。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号